OKYO Pharma Limited - Bathi sadurunge bunga, pajak, lan amortisasi OKYO

The prospects of OKYO Pharma Limited (OKYO) depend on the success of Phase 2 clinical trials and potential merger deals. Operating cash flow before depreciation demonstrates the actual scale of the business, where the 0.00 level reflects the current magnitude. Therapy accessibility is ensured through pharmacy chains; however, high R&D costs and the lack of stable revenue create significant financial risks.

The EBITDA dynamics of OKYO Pharma Limited (OKYO) reflect its status as a biopharmaceutical issuer heavily dependent on the success of its dry eye syndrome drug. This indicator measures net cash flow from core operations excluding depreciation and debt service, allowing for an assessment of real business efficiency and the risk of overpaying for the asset during sharp trend reversals.